KURA ONCOLOGY, INC. (KURA)

Every figure this model derived for KURA, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 5,672,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 519,025,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 559,439,000 AssetsCurrent 2026-06-30
current liabilities 118,193,000 LiabilitiesCurrent 2026-06-30
equity 48,431,000 StockholdersEquity 2026-06-30
interest expense 1,420,000 InterestExpenseNonoperating 2026-06-30
ocf -111,757,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 77,225,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 38,942,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up KURA on one particular measure came for.

RatioValue
cash operating margin-359.8
current ratio8.92
current ratio reported4.73
deferred revenue growth12.23
dilution pct1.76
fcf margin-152.06
interest cover-224.01
operating margin-411.9
owner earnings margin-202.49
sbc pct revenue50.43

What to be careful about

What this model itself distrusts about KURA's figures. Written by the derivation as it ran, not added afterwards.